Cetera Investment Advisers Has $1.97 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Cetera Investment Advisers lifted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 94.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 57,919 shares of the company’s stock after buying an additional 28,084 shares during the period. Cetera Investment Advisers owned about 0.07% of CRISPR Therapeutics worth $1,971,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. lifted its stake in CRISPR Therapeutics by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after purchasing an additional 1,074,238 shares during the last quarter. Capital International Investors lifted its stake in CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock valued at $344,145,000 after purchasing an additional 816,789 shares during the last quarter. Baker BROS. Advisors LP lifted its stake in CRISPR Therapeutics by 55.1% in the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company’s stock valued at $51,483,000 after purchasing an additional 464,936 shares during the last quarter. Bank of America Corp DE lifted its stake in CRISPR Therapeutics by 12.0% in the 4th quarter. Bank of America Corp DE now owns 1,211,509 shares of the company’s stock valued at $47,685,000 after purchasing an additional 129,746 shares during the last quarter. Finally, Two Sigma Investments LP lifted its stake in CRISPR Therapeutics by 71.1% in the 4th quarter. Two Sigma Investments LP now owns 306,272 shares of the company’s stock valued at $12,055,000 after purchasing an additional 127,219 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Bank of America cut their target price on shares of CRISPR Therapeutics from $79.00 to $78.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Royal Bank Of Canada raised their price objective on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a “sector perform” rating in a research report on Tuesday. HC Wainwright raised their price objective on shares of CRISPR Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday. The Goldman Sachs Group cut their price objective on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating for the company in a research report on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Friday, May 16th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $71.60.

CRISPR Therapeutics Trading Down 1.7%

Shares of CRSP opened at $55.00 on Friday. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $71.13. The firm’s 50 day moving average is $51.60 and its 200-day moving average is $43.92. The stock has a market capitalization of $5.00 billion, a PE ratio of -10.13 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.18. The business had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The firm’s quarterly revenue was up 72.5% compared to the same quarter last year. During the same period last year, the firm posted ($1.49) earnings per share. Equities research analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider directly owned 6,068 shares of the company’s stock, valued at $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Simeon George acquired 989,812 shares of the firm’s stock in a transaction that occurred on Wednesday, July 16th. The stock was purchased at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the purchase, the director directly owned 1,730,179 shares of the company’s stock, valued at $90,021,213.37. The trade was a 133.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 4.30% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.